J&J Reports Long-Term Extension Results from GALAXI-2, GALAXI-3, and GRAVITI Trials of Tremfya (Guselkumab) for Crohn’s Disease

Shots:

• J&J has reported 96wk. P-III trial data in mod. to sev. Crohn’s Disease incl. GRAVITI (SC induction: 400mg Q4W; maintenance: 200mg at Wk. 12 then Q4W or 100mg at Wk. 16 then Q8W) vs PBO, & GALAXI 2 & 3 (IV induction: 200mg Q4W; SC maintenance) vs Stelara
• In GRAVITI, 92% (100mg) & 93.4% (200mg) had clinical remission, plus 38.7% & 44.1% showed deep remission. Also, 41.5% & 46% had endoscopic remission, with 65% & 65.1% showing endoscopic response
• In pooled GALAXI 2 & 3 trials, SC maintenance at Wk. 96 showed clinical remission in 86.7% (100mg) & 87.1% (200mg), deep remission in 51.2% & 49%, endoscopic remission in 56.3% & 56.6%, with endoscopic response in 73.6% & 70.7%; data presented at ACG’25

Ref: Johnson & Johnson | Image: Johnson & Johnson | Press Release

Related News:- Johnson & Johnson Reports the US FDA’s sNDA Acceptance & Priority Review of Akeega to Treat Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com